ArticleJournal of thoracic disease2026
SCARNA20 influences the occurrence and development of lung cancer by inhibiting tumor cell proliferation, migration, and invasion.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality with limited treatment efficacy. Small nucleolar RNAs (snoRNAs) have emerged as potential key players in tumorigenesis, but their roles in NSCLC are largely unexplored. Our previous study identified SCARNA20 as significantly downregulated in NSCLC tissues, suggesting a potential tumor-suppressive function. Thus, in order to further explore the role of SCARNA20 in NSCLC, we conducted this study to verify its function. Methods: The biological functions of SCARNA20 were investigated Results: Overexpression of SCARNA20 significantly inhibited NSCLC cell proliferation, colony formation, migration, and invasion Conclusions: SCARNA20 acts as a tumor suppressor in NSCLC, inhibiting malignant phenotypes including cell proliferation, migration, and invasion, both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.